7
Participants
Start Date
September 25, 2019
Primary Completion Date
June 30, 2024
Study Completion Date
June 30, 2026
Sirolimus
Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
Children's Hospital of Philadelphia, Philadelphia
University of Pennsylvania, Philadelphia
University of Arkansas for Medical Sciences, Little Rock
University of California - San Diego, La Jolla
University of Pennsylvania
OTHER